Ildiko Lingvay

433 total papers · 40.9k total citations
218 papers, 15.1k citations indexed

About

Ildiko Lingvay is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ildiko Lingvay has authored 218 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 188 papers in Endocrinology, Diabetes and Metabolism, 108 papers in Molecular Biology and 52 papers in Surgery. Recurrent topics in Ildiko Lingvay's work include Diabetes Treatment and Management (163 papers), Metabolism, Diabetes, and Cancer (104 papers) and Diabetes Management and Research (70 papers). Ildiko Lingvay is often cited by papers focused on Diabetes Treatment and Management (163 papers), Metabolism, Diabetes, and Cancer (104 papers) and Diabetes Management and Research (70 papers). Ildiko Lingvay collaborates with scholars based in United States, Denmark and United Kingdom. Ildiko Lingvay's co-authors include Melanie J. Davies, Thomas A. Wadden, Julio Rosenstock, Sean Wharton, Robert F. Kushner, John Wilding, Barbara McGowan, Rachel L. Batterham, Luc F. Van Gaal and Koutaro Yokote and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Ildiko Lingvay

207 papers receiving 14.8k citations

Hit Papers

Once-Weekly Semaglutide i... 2017 2026 2020 2023 2021 2019 2023 2021 2021 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    2021 2.4k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →
  2. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    2019 1.2k citations Mansoor Husain, Andreas L. Birkenfeld et al. New England Journal of Medicine profile →
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    2023 1.2k citations A. Michael Lincoff, Kirstine Brown‐Frandsen et al. New England Journal of Medicine profile →
  4. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    2021 770 citations Melanie J. Davies, Louise Færch et al. The Lancet profile →
  5. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
    2021 626 citations Thomas A. Wadden, Timothy S. Bailey et al. JAMA profile →
  6. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
    2018 548 citations Richard E. Pratley, Vanita R. Aroda et al. The Lancet Diabetes & Endocrinology profile →
  7. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
    2022 485 citations John Wilding, Rachel L. Batterham et al. Diabetes Obesity and Metabolism profile →
  8. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
    2017 434 citations Andrew Ahmann, Matthew Capehorn et al. Diabetes Care profile →
  9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial
    2019 402 citations Richard E. Pratley, Aslam Amod et al. The Lancet profile →
  10. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
    2021 335 citations Ildiko Lingvay, Priya Sumithran et al. The Lancet profile →
  11. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
    2023 186 citations Juan P. Frías, Srikanth Deenadayalan et al. The Lancet profile →
  12. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    2022 154 citations John A. Spertus, Mary C. Birmingham et al. Nature Medicine profile →
  13. Semaglutide for the treatment of overweight and obesity: A review
    2022 123 citations Natasha C. Bergmann, Melanie J. Davies et al. Diabetes Obesity and Metabolism profile →
  14. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
    2024 113 citations Mikhail Kosiborod, John Deanfield et al. The Lancet profile →
  15. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
    2024 111 citations Donna H. Ryan, Ildiko Lingvay et al. Nature Medicine profile →
  16. Obesity in adults
    2024 111 citations Ildiko Lingvay, Ricardo V. Cohen et al. The Lancet profile →
  17. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
    2024 96 citations Helen M. Colhoun, Ildiko Lingvay et al. Nature Medicine profile →
  18. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
    2024 91 citations John Deanfield, Subodh Verma et al. The Lancet profile →
  19. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
    2023 89 citations Julio Rosenstock, Stephen C. Bain et al. New England Journal of Medicine profile →
  20. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes
    2023 82 citations Ildiko Lingvay, Cyrus Desouza et al. JAMA profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ildiko Lingvay 10.7k 5.1k 4.5k 3.7k 3.2k 218 15.1k
M Hanefeld 12.8k 1.2× 6.1k 1.2× 2.2k 0.5× 3.3k 0.9× 2.7k 0.8× 308 18.6k
W. Timothy Garvey 5.5k 0.5× 2.9k 0.6× 3.2k 0.7× 3.9k 1.1× 5.0k 1.6× 164 14.3k
Απόστολος Τσάπας 16.8k 1.6× 6.8k 1.3× 2.1k 0.5× 5.3k 1.4× 2.3k 0.7× 160 21.0k
Alan J. Garber 9.0k 0.8× 3.9k 0.8× 1.8k 0.4× 3.8k 1.0× 2.1k 0.6× 142 13.2k
Juan P. Frías 8.1k 0.8× 3.8k 0.7× 3.0k 0.7× 2.8k 0.7× 2.4k 0.7× 172 11.1k
Robert E. Ratner 11.0k 1.0× 3.8k 0.7× 1.5k 0.3× 5.1k 1.4× 1.9k 0.6× 159 17.0k
Michaëla Diamant 10.8k 1.0× 5.4k 1.1× 1.3k 0.3× 4.3k 1.1× 2.6k 0.8× 227 19.4k
Tina Vilsbøll 14.7k 1.4× 6.9k 1.3× 2.6k 0.6× 8.1k 2.2× 3.3k 1.0× 455 20.1k
Jorge Plutzky 4.3k 0.4× 7.9k 1.5× 1.8k 0.4× 4.0k 1.1× 3.2k 1.0× 185 17.9k
Ramón Gomis 8.6k 0.8× 3.8k 0.7× 1.4k 0.3× 3.1k 0.8× 1.9k 0.6× 173 14.8k

Countries citing papers authored by Ildiko Lingvay

Since Specialization
Citations

This map shows the geographic impact of Ildiko Lingvay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ildiko Lingvay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ildiko Lingvay more than expected).

Fields of papers citing papers by Ildiko Lingvay

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ildiko Lingvay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ildiko Lingvay. The network helps show where Ildiko Lingvay may publish in the future.

Co-authorship network of co-authors of Ildiko Lingvay

This figure shows the co-authorship network connecting the top 25 collaborators of Ildiko Lingvay. A scholar is included among the top collaborators of Ildiko Lingvay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ildiko Lingvay. Ildiko Lingvay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Loading papers...

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Muggeo Breakdown of academic impact, for papers by Steen Steenken Breakdown of academic impact, for papers by Simon Gaisford Breakdown of academic impact, for papers by Tian‐Fu Liu Breakdown of academic impact, for papers by Ellen B. Gold Breakdown of academic impact, for papers by Tony Miller Breakdown of academic impact, for papers by Dan Binkley Breakdown of academic impact, for papers by Larry Stitt
Rankless by CCL
2026